Midwest Messenger (Sept. 28) – Aptimmune Biologics Inc., a St. Louis, Missouri-based biotechnology company that focuses on developing swine vaccines, has been working on an ASF vaccine for more than a decade — since the moment Aptimmune’s founder, Dr. Federico Zuckermann, realized that he already had the building blocks for a vaccine. Scientists are currently working at the federal Plum Island Animal Disease Center to test a potential vaccine against African Swine Fever. Eventually Aptimmune scientists will lead the vaccine registration process to get vaccines into affected countries, as well as stock the U.S. with vaccines for a potential outbreak.
Novel Cell Line Advances African Swine Fever Vaccine Research
